Trials / Unknown
UnknownNCT05099913
The Role of Neuromodulators in Refractory Functional Dyspepsia
Short-term and Low-dose Application of Neuromodulators Increases Treatment Efficacy and Minimizes Antidepressant Discontinuation Syndrome in Refractory Functional Dyspepsia
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to investigate the effect of central neuromodulators on refractory functional dyspepsia
Detailed description
Functional dyspepsia (FD) is a prevalent disease combined with emotional disorders. Antidepressants are beneficial in the treatment of refractory FD, while for the long-term use of antidepressants, it could lead to withdrawal syndrome or other adverse events. Refractory FD patients were unsatisfied with the regular first-line anti-acid treatment. However, many patients were worried about taking antidiepressants, even though guideline has recommended antidepressant use in FD. In our study, we would use low-dose and short-term antidepressant in refractory FD patients, and investigate whether short-term antidepressants application would improve therapeutic efficacy and minimize antidepressant withdrawal of FD patients.
Conditions
- Dyspepsia
- Functional Gastrointestinal Disorders
- Antidepressant Discontinuation Syndrome
- Antidepressant Drug Adverse Reaction
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deanxit | Central neuromodulators was applied in refractory FD patients for different time |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2022-10-01
- Completion
- 2022-12-30
- First posted
- 2021-10-29
- Last updated
- 2022-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05099913. Inclusion in this directory is not an endorsement.